Tag: Eli Lilly and Company

Pfizer and Lilly’s OA Pain Drug Hit Endpoints

Pfizer and Eli Lilly and Company announced that their tanezumab hit two out of three co-primary endpoints in one dose and all three with a higher dose in patients with moderate-to-severe osteoarthriti...

Companies with Most FDA Approvals

In 2018, the U.S. Food and Drug Administration (FDA) approved 59 novel drugs, meaning approved new molecular entities (NMEs). The figure for 2017 was 46 novel drugs. The FDA notes, “Each year, CDER a...

Eli Lilly signs R&D licensing agreement with Aduro Biotech

Eli Lilly and Company and Aduro Biotech announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program.

PAREXEL and Eli Lilly to start a new clinical research program

PAREXEL, a life sciences consulting firm and contract research organization, announced a collaboration with Eli Lilly to launch a clinical research learning and development program in China.

Scientists unveiled a more effective approach for assessing drug response

drug development
Scientists from Eli Lilly, the Icahn School of Medicine and Sema4 released results from a study demonstrating that patient-derived cells offer a more effective approach for assessing drug response.

Eli Lilly licenses diabetes drug from Chugai Pharmaceutical

Chugai Pharmaceutical and Eli Lilly and Company announced they have entered into a license agreement for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist.

Anima Biotech signs a drug discovery agreement with Lilly

Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima's Translation Control Therapeutics platform.

Lilly and Sigilon Therapeutics join forces to develop diabetes treatment

Eli Lilly and Company and Sigilon Therapeutics announced a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes.

Eli Lilly obtained EU marketing authorization for anti-rheumatic drug

Eli Lilly and Company announced that the European Commission has granted marketing authorisation for Taltz, alone or in combination with methotrexate, for the treatment of active psoriatic arthritis

Curevac launches the construction of new GMP-compliant RNA production plant

CureVac AG announced the groundbreaking of its industrial-scale, GMP-compliant production facility at its headquarters in Tübingen, Germany

Lilly plans $72 million investment in insulin manufacturing

Eli Lilly and Company today announced plans to invest $72 million in an insulin manufacturing project at one of its facilities

Eli Lilly and CureVac set up a global immuno-oncology collaboration

eli lilly
Eli Lilly and CureVac have announced an immuno-oncology collaboration focused on the development and commercialization of potential cancer vaccine products

Lilly will collaborate with KeyBioscience AG on diabetes treatment

Eli Lilly and Company and KeyBioscience AG have agreed to a new collaboration focused on the development of Dual Amylin Calcitonin Receptor Agonists